Evotec and Roche have entered into an exclusive worldwide agreement for the development and commercialization of Evotec’s MAO-B inhibitor in patients with Alzheimer’s disease (AD). Roche will pay Evotec an upfront fee of $10 million, and as much as $820 million in development and commercial milestone payments, as well as tiered double-digit royalties on sales. Roche will initiate studies in 2012 to demonstrate proof of concept and will be responsible for all clinical development, man...